Key Takeaways
- • Walgreens Boots Alliance has launched a formal auction of Boots with a midnight deadline for first-round bids, with the high street chemist expected to command a valuation of £10 billion ($12.7 billion USD equivalent).
- • A competitive bidding process is underway involving multiple tier-one private equity firms including Bain Capital, Sycamore Partners, Advent, and Apollo, alongside the Issa brothers (Asda owners) with TDR Capital as their PE backer.
- • Boots operates 2,200 stores globally with 51,000 employees and generates significant EBITDA, though the business faced pandemic-related headwinds including a £258 million loss in the year to August 2020 and subsequent workforce reductions.
- • The carve-out from Walgreens Boots Alliance represents a continuation of private equity interest in legacy British retail and healthcare assets, following KKR's 2007 acquisition and subsequent 2014 merger with Walgreens.
- • A successful buyer will inherit a business with deep historical roots (founded 1849) but requiring operational turnaround and potential portfolio optimization, typical of large PE platform acquisitions in mature markets.
Summary
Walgreens Boots Alliance has initiated a formal divestiture process for Boots, setting a midnight deadline for initial binding offers in what is expected to be one of 2026's largest private equity-backed transactions. The pharmacy and health and beauty retailer is being marketed to potential acquirers at a valuation approaching £10 billion, representing a significant write-down from its historical valuations but reflecting current market conditions for mature British retail assets.
The auction has attracted a competitive field of bidders spanning multiple private equity styles and strategies. Bain Capital, which recently exited a failed bid for LV, has tabled an offer alongside other prominent firms including Sycamore Partners, Advent, and Apollo Global Management. The Issa brothers—known for their acquisition and operational turnaround of Asda—are pursuing a consortium bid with TDR Capital backing their equity position. This multi-bidder dynamic suggests strong conviction among institutional capital that Boots' platform can be restructured profitably.
Boots' operational scale and market position remain substantial despite recent performance challenges. The business operates 2,200 retail locations globally and employs approximately 51,000 staff across its international footprint. However, the company experienced significant losses during the pandemic period, posting a £258 million loss in the financial year ending August 31, 2020, with subsequent workforce reductions implemented to stabilize the cost structure. The business traces its origins to 1849 and represents one of Britain's most recognizable health and beauty retail brands, though its strategic positioning within mature pharmacy markets requires modernization.
The proposed carve-out continues a multi-decade trajectory of ownership transitions. Boots merged with European pharmaceutical distributor Alliance Unichem in 2006 to form Alliance Boots, which was subsequently acquired by KKR in a leveraged buyout in 2007. The business then consolidated with American pharmacy giant Walgreens in 2014, forming the current publicly traded Walgreens Boots Alliance structure. Walgreens' decision to divest reflects portfolio optimization and shareholder value realization strategies, with the separation allowing Boots to operate as an independent platform under new ownership better suited to international pharmacy and retail markets.
The midnight deadline for first-round bids indicates an accelerated timeline typical of large-cap PE auctions, with final bids and deal closure likely proceeding through Q4 2026. The transaction will be scrutinized by stakeholders including Boots' 51,000 employees, its 2,200 store operators, and pharmacy supply chain partners in the UK and internationally, given the operational complexity and regulatory considerations inherent in divesting a major healthcare retail platform.
The auction has attracted a competitive field of bidders spanning multiple private equity styles and strategies. Bain Capital, which recently exited a failed bid for LV, has tabled an offer alongside other prominent firms including Sycamore Partners, Advent, and Apollo Global Management. The Issa brothers—known for their acquisition and operational turnaround of Asda—are pursuing a consortium bid with TDR Capital backing their equity position. This multi-bidder dynamic suggests strong conviction among institutional capital that Boots' platform can be restructured profitably.
Boots' operational scale and market position remain substantial despite recent performance challenges. The business operates 2,200 retail locations globally and employs approximately 51,000 staff across its international footprint. However, the company experienced significant losses during the pandemic period, posting a £258 million loss in the financial year ending August 31, 2020, with subsequent workforce reductions implemented to stabilize the cost structure. The business traces its origins to 1849 and represents one of Britain's most recognizable health and beauty retail brands, though its strategic positioning within mature pharmacy markets requires modernization.
The proposed carve-out continues a multi-decade trajectory of ownership transitions. Boots merged with European pharmaceutical distributor Alliance Unichem in 2006 to form Alliance Boots, which was subsequently acquired by KKR in a leveraged buyout in 2007. The business then consolidated with American pharmacy giant Walgreens in 2014, forming the current publicly traded Walgreens Boots Alliance structure. Walgreens' decision to divest reflects portfolio optimization and shareholder value realization strategies, with the separation allowing Boots to operate as an independent platform under new ownership better suited to international pharmacy and retail markets.
The midnight deadline for first-round bids indicates an accelerated timeline typical of large-cap PE auctions, with final bids and deal closure likely proceeding through Q4 2026. The transaction will be scrutinized by stakeholders including Boots' 51,000 employees, its 2,200 store operators, and pharmacy supply chain partners in the UK and internationally, given the operational complexity and regulatory considerations inherent in divesting a major healthcare retail platform.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.